Neurokinin-1 (NK 1 ) receptor antagonists (RAs) are commonly coadministered with serotonin (5-HT 3 ) RAs (e.g. palonosetron (PALO)) to prevent chemotherapy-induced nausea/vomiting. Netupitant/palonosetron (NEPA), an oral fixed combination of netupitant (NETU)-a new NK 1 RA-and PALO, is currently under development. In vitro data suggest that NETU inhibits CYP3A4 and is a substrate for and weak inhibitor of P-glycoprotein (P-gp). This review evaluates potential drug-drug interactions between NETU or NEPA and CYP3A4 substrates/inducers/inhibitors or P-gp substrates in healthy subjects. Pharmacokinetic (PK) parameters were evaluated for each drug when NETU was coadministered with PALO (single doses) and when single doses of NETU or NEPA were coadministered with CYP3A4 substrates (erythromycin (ERY), midazolam (MID), dexamethasone (DEX), or oral contraceptives), inhibitors (ketoconazole (KETO)), or inducers (rifampicin (RIF)), or a P-gp substrate (digoxin (DIG)). Results showed no relevant PK interactions between NETU and PALO. Coadministration of NETU increased MID and ERY exposure and significantly increased DEX exposure in a dose-dependent manner; NETU exposure was unaffected. NEPA coadministration had no clinically significant effect on oral contraception, although levonorgestrel exposure increased. NETU exposure increased after coadministration of NEPA with KETO and decreased after coadministration with RIF; PALO exposure was unaffected. NETU coadministration did not influence DIG exposure. In conclusion, there were no clinically relevant interactions between NETU and PALO, or NEPA and oral contraceptives (based on levonorgestrel and ethinylestradiol exposure). Coadministration of NETU or NEPA with CYP3A4 inducers/inhibitors/substrates should be done with caution. Dose reduction is recommended for DEX. Dose adjustments are not needed for NETU coadministration with P-gp substrates.
Introduction
Neurokinin-1 (NK 1 ) receptor antagonists (RAs) and serotonin (5-HT 3 ) RAs are two classes of agents recommended for prevention of chemotherapy-induced nausea/vomiting (CINV). [1] [2] [3] CINV is thought to arise via multiple pathways that are activated by various neurotransmitters, most notably serotonin (5-HT) and substance P, among others. 4 The 5-HT 3 RAs (ondansetron, dolasetron, granisetron, palonosetron (PALO)) modulate emetic pathways via inhibition of 5-HT 3 receptors located in both the gastrointestinal tract and the central nervous system. 4 ,5 NK 1 RAs (e.g. aprepitant and fosaprepitant) prevent binding of substance P at NK 1 receptors, which are located in the gut, area postrema, and nucleus tractus solitarius (areas involved in the emetic reflex). 5 Because their mechanisms of action target different neurotransmitter pathways involved in nausea and vomiting, combination therapy with a 5-HT 3 RA and NK 1 RA represents a rational therapeutic strategy. 5 Indeed, several studies have demonstrated the efficacy of such combinations, 6 and several guidelines recommend this combination (plus a steroid) for managing CINV associated with highly emetogenic chemotherapy regimens. [1] [2] [3] Netupitant/palonosetron (NEPA) is an oral fixed combination of netupitant (NETU, 300 mg) and PALO (0.5 mg) recently approved for prevention of acute and delayed CINV. NETU is a novel, highly selective NK 1 RA. 7 PALO is a pharmacologically distinct 5-HT 3 RA in that it has a different pharmacokinetic (PK) profile and molecular binding profile, 8 triggers receptor internalization, 9 demonstrates prolonged inhibition of 5-HT 3 receptor function, 8, 9 and inhibits 5-HT 3 -NK 1 crosstalk. 10 These characteristics may be responsible for its prolonged duration of action and greater efficacy in preventing delayed CINV (24-120 h after chemotherapy) versus single doses of other 5-HT 3 RAs. 11, 12 A recent in vitro study demonstrated a synergistic effect of NETU and PALO on inhibition of substance P-mediated responses, 13 and both NETU and PALO triggered NK 1 receptor internalization.
14 Administration of these two agents as a single oral dose may provide a convenient and noninvasive means of administering guidelinebased 1, 3 antiemetic prophylaxis. Reported results from clinical trials to date have demonstrated the efficacy of NEPA in preventing CINV associated with highly and moderately emetogenic chemotherapy. [15] [16] [17] [18] In a Phase 2 study, patients receiving NEPA had higher rates of complete response (CR; no emesis, no rescue medication) and secondary endpoints (no emesis, no significant nausea, and complete protection (CR + no significant nausea)) in the overall phase compared with patients who received PALO alone. 17 In one Phase 3 study, patients receiving NEPA had higher CR rates in the delayed, acute, and overall phases than those receiving PALO alone, as well as higher rates of no emesis and no significant nausea during the delayed and overall phases. 15 Efficacy of NEPA over multiple cycles of chemotherapy was demonstrated in two Phase 3 studies. 16, 18 In all studies, NEPA was well tolerated, with a safety profile similar to that of controls (e.g. PALO alone, PALO plus aprepitant, or aprepitant plus ondansetron). [15] [16] [17] [18] The drug-drug interaction (DDI) profile of any potentially new antiemetic is an important consideration for its place in therapy. As outlined already, combination therapy with multiple antiemetic agents is necessary to target the many pathways that are stimulated after chemotherapy administration. In addition, often these patients are on many other chronic medications as well as the chemotherapy they are receiving so the possibility of DDIs generally is heightened. PALO is primarily metabolized by cytochrome P450 (CYP) enzyme 2D6 (CYP2D6), and to a lesser extent, by CYP3A4 and CYP1A2. 19 In vitro studies demonstrated that PALO neither inhibits nor induces activity of CYP enzymes. 20 NETU is primarily metabolized by CYP3A4. 21 In vitro data suggest that NETU inhibits CYP3A4 22 and is a substrate for and a weak inhibitor of P-glycoprotein (P-gp) 23 but does not inhibit CYP1A2, 2C9, 2C19, or 2D6. 22 In this article, we review a series of clinical studies that were conducted to evaluate potential DDIs with NETU or NEPA.
Combination 5-HT 3 and NK 1 RA NETU and PALO Because NETU and PALO will be used as an oral fixed combination in clinical practice, it is important to determine whether coadministration affects the PK profile of either drug. A randomized, open-label, singledose, three-period crossover study assessed the effects of PALO on the PKs of NETU and the effects of NETU on the PKs of PALO. 21 Healthy subjects (nine men and nine women aged 18-43) received single doses of NETU (450 mg PO) alone, PALO (0.75 mg PO) alone, and NETU and PALO combined, with a minimum 14-day washout before the following period. The primary PK parameters of interest included maximum serum concentration (C max ) and area under the curve (AUC) from administration to the last sampling point (AUC last ) and extrapolated to infinity (AUC inf ). Logtransformed values were analyzed using analysis of covariance. Safety assessments included adverse events (AEs), physical exam, vital signs, electrocardiogram (ECG), and laboratory tests.
C max , AUC last , and AUC inf for PALO were similar after administration alone and in combination with NETU. Exposure to PALO was slightly higher after coadministration with NETU, but the difference appeared to be of no clinical relevance (i.e. 90% confidence intervals (CIs) of the geometric mean ratios of PK parameters associated with the drugs given alone or in combination fell within the classical bioequivalence limits of 80%-125%) ( Table 1 ). C max , AUC last , and AUC inf for NETU were similar after administration alone and in combination with PALO. The most common AEs were headache (61%), nasopharyngitis (39%), nausea (28%), somnolence (28%), constipation (17%), abdominal pain (17%), abdominal pain upper (11%), and dizziness (11%). All AEs were mild or moderate in intensity; overall, the study treatments were well tolerated by subjects.
This study demonstrated that there were no clinically (nor statistically) relevant PK interactions between NETU and PALO with single doses of 450 mg and 0.75 mg, respectively. 21 Of note, these doses are higher than those used in the NEPA combination product.
NETU or NEPA and CYP3A4 substrates NETU and midazolam or erythromycin
As noted above, in vitro data suggest that NETU moderately inhibits CYP3A4. 22 Midazolam (MID) and erythromycin (ERY) are representative CYP3A4 substrates 24 and can be used as probes to determine whether and the extent to which NETU affects CYP3A4 activity in healthy volunteers. The impact of NETU on the PKs of MID and ERY, and the effect of MID or ERY on the PKs of NETU, were assessed in a single-dose, three-period crossover study. 24 Subjects (20 healthy men, age range 20-32) were randomly assigned to one of four treatment sequences with oral MID (7.5 mg) or ERY (500 mg) alone alternating with oral NETU (300 mg) alone, followed by a combination of MID or ERY with NETU (minimum three-week washout between periods). Endpoints included PK parameters for MID, ERY, and NETU, including C max , time to maximum serum concentration (t max ), elimination half-life (t 1/2 ), AUC last , and AUC inf . Safety assessments included routine laboratory tests, physical exams, vital signs, 12-lead ECGs, and AEs.
Exposure to MID was significantly increased when coadministered with NETU (Table 2) ; mean C max increased by 40%, and mean AUC was 144% higher ( Figure 1 ). Exposure to ERY was significantly increased when coadministered with NETU (Table 2) ; mean C max and AUC were both 30% higher. The PKs of NETU were not significantly altered by coadministration with MID or ERY. Treatments were well tolerated: the majority of AEs were mild, and the most frequent were fatigue (10%), headache (8.3%), lethargy (6.7%), and nausea (5%); no serious AEs or deaths occurred during the study. No clinically significant changes in laboratory parameters, vital signs, or ECGs were observed.
This study demonstrated that coadministration of single doses of NETU, at doses intended for CINV prophylaxis, altered the PKs of MID and ERY via moderate inhibition of CYP3A4 metabolism. Exposure of NETU following a single dose of 300 mg was unaffected by coadministration with either of the CYP3A4 substrates, ERY or MID, at therapeutic doses. 24 
NETU and dexamethasone
Dexamethasone (DEX) is a substrate of CYP3A4. 24 Considering the likelihood that NETU or NEPA will be coadministered with DEX in clinical practice, this potential DDI is of particular clinical interest. The effects of NETU on the PKs of DEX (primary objective) were assessed in 25 healthy adults (14 men and 11 women aged 18-42). 24 Secondary objectives of the study were to assess the safety and tolerability of NETU with concomitant administration of DEX and the effects of DEX on the PKs of NETU. In a randomized, open-label, three-period crossover study, NETU increased exposure to DEX in a dose-dependent manner (Figure 2 , Table 3 ). On Day 1, DEX mean AUC 0-24 increased by 48%, 72%, and 75% with coadministration of 100, 300, and 450 mg NETU, respectively, while C max was only slightly affected (9%-20% increases). On Day 4, DEX mean AUC 84-108 increased by 75%, 140%, and 170% with coadministration of 100, 300, and 450 mg NETU, respectively. On Days 2 and 4, DEX C max increased by 49%-79%. DEX C min on Days 2-4 was increased approximately 180%, 330%, and 360% with coadministration of 100, 300, and 450 mg NETU, respectively. The PK profile of NETU was not significantly altered in the presence of DEX; PK parameters for NETU were comparable to results obtained in previous studies in which the same doses of NETU were administered alone. Treatments were well tolerated: the most common AEs were acne (56%), headache (56%), nausea (40%), flushing (36%), nasopharyngitis (32%), fatigue (24%), and insomnia (24%). No deaths or serious AEs occurred during the study. No clinically significant changes in laboratory parameters, vital signs, or ECGs were noted.
This study demonstrated that coadministration of single doses of NETU significantly increased exposure to DEX in a dose-dependent manner, and the findings suggest that oral doses of DEX should be reduced by $50% when given in combination with NETU. Therapeutic doses of DEX when administered with NETU appear to have no effect on the exposure of NETU. 24 
NEPA and ethinylestradiol or levonorgestrel
DDIs that reduce the efficacy of oral contraceptives are also of interest as a potential scenario that may need to be managed in clinical practice. The effect of NEPA on the PKs of ethinylestradiol (EE) and levonorgestrel (LEVO) was evaluated in a randomized, open-label, single-dose, two-period crossover study. 21 Subjects (24 healthy women aged 19-40) received single doses of EE/LEVO (60 lg/300 lg PO) alone and in combination with NEPA (300 mg/0.5 mg PO) with a minimum 28-day washout between periods. Endpoints included PK parameters for EE and LEVO: C max , AUC last , and AUC inf . Safety assessments included AEs, vital signs, physical exam, ECG, and clinical laboratory tests.
PK parameters for EE and LEVO are summarized in Table 4 . NEPA did not significantly affect exposure to EE, with AUC last and AUC inf increased by 16% and 12%, respectively. These changes were not clinically relevant, as the 90% CIs were within the 80%-125% bioequivalence range. C max for LEVO was not altered following coadministration with NEPA. However, the extent of LEVO exposure was significantly higher after NEPA coadministration. AUC last and AUC inf for LEVO were 46% and 40% higher, respectively, and the 90% CIs were outside the 80%-125% bioequivalence range. The most common AEs were headache (58%), nausea (29%), constipation (25%), fatigue (21%), dizziness (13%), diarrhea (8%), vomiting (8%), and metrorrhagia (8%). All AEs were mild to moderate in intensity; no subjects experienced serious clinical, laboratory, or other AEs.
These data demonstrate that coadministration of single doses of NEPA did not significantly affect exposure to EE. Although NEPA coadministration increased exposure to LEVO by approximately 40%, the observed change is not considered clinically relevant. Therefore, no dose adjustment or precaution is necessary. 21 NEPA and CYP3A4 inhibitors and inducers NEPA and ketoconazole or rifampicin As a substrate of CYP3A4, NETU is also susceptible to DDIs with CYP3A4 inhibitors or inducers that may affect its PKs. One study evaluated coadministration of NEPA with a strong CYP3A4 inhibitor (ketoconazole (KETO)) or a strong CYP3A4 inducer (rifampicin (RIF)). 21 A two-group, two-way crossover study was conducted to assess the effect of KETO and RIF on the PKs of NEPA in healthy subjects. Subjects (21 men and 15 women, age range 32-55) received a single oral dose of NEPA on Day 1, alone or in combination with KETO (400 mg PO QD, from Days -2 to 10) or RIF (600 mg PO QD, from Days -7 to 10), with a minimum 28-day washout period between NEPA doses (half the subjects received KETO and half received RIF). Endpoints included PK parameters for NETU and PALO including C max , AUC last , and AUC 0-inf ; safety assessments included AEs, laboratory parameters, vital signs, and ECG.
NETU exposure was significantly increased after administration of NEPA in combination with KETO, with an increase of 80% for AUC last , 140% for AUC 0-inf , and 25% for C max (Table 5 ). PALO exposure was not significantly affected by KETO coadministration. NETU exposure was significantly decreased after administration of NEPA in combination with RIF, with a decrease of 82% for AUC last , 83% for AUC 0-inf , and 62% for C max (Table 6) . AUC last and AUC 0-inf for PALO were slightly decreased (19%) by coadministration with RIF; these changes were not considered clinically relevant, and the 90% CIs were within the predefined 80%-125% equivalence range. The most common AEs were fatigue (57%), headache (40%), nasopharyngitis (20%), diarrhea (11%), abdominal pain (9%), constipation (9%), nausea (9%), and rhinitis (9%). Most of the observed AEs were of mild intensity (101 of 107 treatment-emergent AEs) and assessed as possibly related to the treatment (92 of 107 treatment-emergent AEs). No events of severe intensity were reported. No subjects experienced serious clinical, laboratory, or other AEs. This study demonstrated that NETU exposure was increased after administration of NEPA in combination with KETO and decreased after administration of NEPA in combination with RIF, while the PKs of PALO were not significantly affected by either KETO or RIF. 21 
P-gp substrates NETU and digoxin
The drug transporter P-gp is another potential source of DDIs, and there is some overlap with CYP3A4 in terms of substrates, inhibitors, and inducers. 25 Digoxin (DIG), a substrate for P-gp, is often used as a probe to assess the effects of drugs on P-gp function.
26
A one-way, fixed-sequence study assessed the effects of NETU on the PKs of DIG at steady state during the first 24-h post-NETU dose in healthy volunteers. 23 Secondary objectives of the study were to evaluate the PKs of NETU given concomitantly with DIG and the safety and tolerability of NETU with concomitant administration of DIG. Sixteen subjects (eight men and eight women) received a DIG loading dose of 3 Â 0.5 mg (0.5 mg PO Q6h) on Day 1, followed by DIG (0.25 mg PO) daily on Days 2-12, with concomitant NETU (450 mg PO) on Day 8. Endpoints included PK parameters for DIG: AUC 0-24,ss (ss¼at steady state), C max,ss , C min,ss ; safety assessments included AEs, vital signs, and laboratory parameters. DIG concentrations and exposure at steady state were not altered following concomitant NETU administration (Figure 3 ). Mean AUC 0-24,ss values were 11.37 lgÁh/mL for NETU plus DIG and 10.96 lgÁh/mL for DIG alone; mean C min,ss values were 0.314 lg/mL and 0.322 lg/mL, respectively. The 90% CIs for AUC 0-24,ss and for C min,ss were within the 80%-125% equivalence limits (95.86%-113.11% and 88.84%-105.14%, respectively). The CIs were slightly outside the upper bound of 125% for C max,ss (90.30%-131.49%), but this was considered not clinically relevant. Excretion of DIG in urine was 55% without NETU compared with 57% after NETU coadministration. There were no gender differences observed in extent of exposure to DIG. The PKs of NETU were comparable to previous study results. Study treatment overall was well tolerated; no safety-related influence of DIG and NETU was observed on safety laboratory, vital sign, and ECG parameters. No clinically meaningful influence on QTc was observed.
No influence on DIG exposure after coadministration of a single dose of NETU was observed. Based on these data, dose adjustment for P-gp substrates is not required when administered concomitantly with NETU. 23 Summary and discussion Table 7 summarizes the overall findings from the studies discussed above. No clinically relevant interactions were observed between NETU and PALO or NEPA and oral contraceptives. 21 However, coadministration 24 Dose adjustments are not needed for NETU coadministration with P-gp substrates. 23 The findings observed in most of these studies are similar to what has been reported in DDI studies involving aprepitant. For example, studies with PALO 27 and DIG 26 administered with aprepitant showed no significant effects of aprepitant on either drug, and dose adjustments are not required. Like NETU, aprepitant is a CYP3A4 substrate and is a moderate inhibitor of CYP3A4;
28 the AUC and half-life of aprepitant were increased following coadministration with KETO and decreased following coadministration with RIF. 29 Studies with MID showed moderate and dosedependent inhibition of CYP3A4 by aprepitant. [29] [30] [31] Likewise, the addition of aprepitant to a standard regimen of ondansetron plus oral DEX significantly increased the AUC 0-24 of DEX, 32 and dose adjustments for oral DEX (50% reduction) are recommended. 31 Aprepitant has also been shown to exert an inductive effect on CYP3A4; in a study using intravenous MID as a probe, administration of a standard three-day regimen of aprepitant was associated with weak CYP3A4 inhibition on Day 4 and weak induction on Day 8, with no effect on Day 15. 33 NETU and its metabolites have not shown any inductive effects on CYP3A4. 34 There are some differences in the DDI profile of aprepitant compared with what is currently known about NETU. For example, while NEPA did not demonstrate a clinically relevant interaction with oral contraceptives, aprepitant may reduce the efficacy of hormonal contraception and a backup method of contraception is recommended. 29, 31 Aprepitant is also a mild inducer of CYP2C9, which can affect the metabolism of tolbutamide. 33 NETU, however, has not been shown to induce CYP2C9. 34 Several studies have evaluated the effects of aprepitant on the PKs of chemotherapeutic agents; aprepitant did not have a clinically significant effect on the PKs of cyclophosphamide, docetaxel, and vinorelbine, and dose adjustments are not required. 31 Systemic exposure to intravenously administered chemotherapeutic agents that are metabolized by CYP3A4 was higher when NEPA was coadministered than when PALO alone was coadministered in cancer patients. Compared with coadministration with PALO alone, following coadministration with NEPA, the mean C max and AUC of docetaxel were 49% and 35% higher, respectively; the mean C max and AUC of etoposide were increased by 10% and 28%, respectively; and the mean C max and AUC for cyclophosphamide were 27% and 20% higher. 34 However, one study of NEPA reported no evidence of cyclophosphamide toxicity 35 and reported safety results from the Phase 2 and Phase 3 studies to date are not suggestive of any clinically significant interactions.
Although not the focus of these studies, the data suggest that clinically significant DDIs between PALO and CYP3A4 inhibitors or inducers are unlikely. This is consistent with the known DDI profile of PALO, 20 and with the generally low potential for clinically significant CYP-mediated DDIs with 5-HT 3 RAs overall. Like PALO, 20 other 5-HT 3 RAs do not appear to significantly inhibit or induce CYP isoenzymes, and coadministration with CYP inducers or inhibitors does not seem to result in clinically significant changes in PKs; the latter may be due, in part, to the fact that these drugs have metabolic pathways that involve multiple CYP isoenzymes (PALO: CYP2D6 (primarily), CYP3A4, and CYP1A2; ondansetron: CYP3A4 (primarily), CYP1A2, and CYP2D6; 36 dolasetron: CYP2D6, CYP3A; 37 granisetron: CYP3A4 (major metabolic pathway) and CYP1A1). 38, 39 While the potential for clinically significant DDIs may differ depending on the specific drugs/metabolic pathways involved, the DDI profile of NEPA seems to be consistent with other 5HT 3 -RA and NK 1 -RA antiemetics. Nevertheless, the potential for PK DDIs may influence the choice of antiemetic therapy on an individual patient basis.
